Peptide therapy for energy levels focuses on compounds that may affect how energized someone feels by influencing underlying physiology. Energy is an output of multiple systems (cellular ATP production, metabolic signalling, body composition, and recovery capacity), and peptides are biological messengers that help coordinate communication among cells, hormones, and organ systems. Shifting these signalling networks and metabolic processes could change perceived physical and mental stamina.
Category 1, Mitochondrial & Cellular-Energy Modulators
includes agents discussed in “energy” contexts because they are linked to ATP generation, redox balance, insulin sensitivity, and metabolic flexibility; processes that help determine endurance and resilience under stress.
MOTS‑C is a 16-amino acid mitochondrial-derived signalling peptide with systemic metabolic effects. It is often discussed as a hormone-like messenger during metabolic stress and in experimental models with pathways tied to glucose handling and cellular stress responses, including AMPK-related signalling. MOTS‑C is also an “exercise mimetic,” meaning it may induce gene-expression patterns resembling exercise adaptation.
Another example is NAD+, which is not a peptide but is commonly grouped with energy-focused interventions. NAD+ is an essential cellular cofactor for energy metabolism, supporting redox reactions that convert nutrients into usable energy. Beyond metabolism, NAD+ availability is also relevant to cellular stress-response enzymes relevant to aging and repair biology.
Category 2, GH / IGF Axis Peptides
can improve energy through sleep, recovery, substrate use, and body composition; domains regulated by growth hormone (GH) and insulin-like growth factor‑1 (IGF‑1).
Tesamorelin is a synthetic GHRH analog that stimulates the pituitary to release endogenous GH, thereby increasing downstream IGF‑1 and influencing metabolism and tissue turnover. Perceived energy may improve via changes in body composition and metabolic efficiency.
Additional GH-axis agents include CJC‑1295, Sermorelin, Ipamorelin, and Hexarelin, each potentially affecting recovery and metabolic signalling via GH/IGF pathways.
Category 3, Metabolic “Exercise-Mimetic” & Enzyme-Targeting Research Compounds
can affect metabolic rate, fuel selection, and mitochondrial adaptation signalling. 5‑Amino‑1MQ is a small molecule linked to NNMT modulation, with potential downstream effects on metabolic efficiency and adipose biology. SLU‑PP‑332 is an exercise-mimetic compound that may activate transcriptional programs related to endurance and fuel utilization in preclinical models.
